CPH vs. CRDL, HLS, OGI, CWEB, GUD, ACB, HTL, QIPT, MDNA, and VHI
Should you be buying Cipher Pharmaceuticals stock or one of its competitors? The main competitors of Cipher Pharmaceuticals include Cardiol Therapeutics (CRDL), HLS Therapeutics (HLS), Organigram (OGI), Charlotte's Web (CWEB), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Hamilton Thorne (HTL), Quipt Home Medical (QIPT), Medicenna Therapeutics (MDNA), and Vitalhub (VHI). These companies are all part of the "medical" sector.
Cipher Pharmaceuticals (TSE:CPH) and Cardiol Therapeutics (TSE:CRDL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation.
Cipher Pharmaceuticals has a net margin of 96.32% compared to Cardiol Therapeutics' net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 28.19% beat Cardiol Therapeutics' return on equity.
Cipher Pharmaceuticals has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cipher Pharmaceuticals received 169 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. However, 69.23% of users gave Cardiol Therapeutics an outperform vote while only 62.68% of users gave Cipher Pharmaceuticals an outperform vote.
In the previous week, Cipher Pharmaceuticals and Cipher Pharmaceuticals both had 1 articles in the media. Cipher Pharmaceuticals' average media sentiment score of 0.20 beat Cardiol Therapeutics' score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the media.
Cipher Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500.
1.1% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.4% of Cardiol Therapeutics shares are owned by institutional investors. 44.5% of Cipher Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Cipher Pharmaceuticals presently has a consensus price target of C$8.00, suggesting a potential downside of 10.61%. Given Cipher Pharmaceuticals' higher possible upside, equities analysts plainly believe Cipher Pharmaceuticals is more favorable than Cardiol Therapeutics.
Summary
Cipher Pharmaceuticals beats Cardiol Therapeutics on 12 of the 14 factors compared between the two stocks.
Get Cipher Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cipher Pharmaceuticals Competitors List
Related Companies and Tools
